Cara Therapeutics, Inc.
Cara Therapeutics, Inc. (CARA) Financial Performance & Income Statement Overview
Review Cara Therapeutics, Inc. (CARA) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Cara Therapeutics, Inc. (CARA) Income Statement & Financial Overview
Access detailed annual and quarterly income data for Cara Therapeutics, Inc. CARA financial performance.
| Metric | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|
| Revenue | $2.56M | $991000.00 | $2.13M | $3.004M |
| Cost of Revenue | $0.00 | $0.00 | $662000.00 | $690000.00 |
| Gross Profit | $2.56M | $991000.00 | $1.47M | $2.31M |
| Gross Profit Ratio | $1.00 | $1.00 | $0.69 | $0.77 |
| R&D Expenses | $1.36M | $9.31M | $21.95M | $28.37M |
| SG&A Expenses | $6.47M | $6.37M | $6.79M | $6.55M |
| Operating Expenses | $8.54M | $18.30M | $28.74M | $34.92M |
| Total Costs & Expenses | $8.86M | $18.30M | $29.40M | $35.61M |
| Interest Income | $0.00 | $0.00 | $0.00 | $874000.00 |
| Interest Expense | $1.96M | $1.91M | $1.98M | $604000.00 |
| Depreciation & Amortization | $73000.00 | $77000.00 | $42000.00 | $82000.00 |
| EBITDA | -$10.44M | -$18.03M | -$28.67M | -$31.65M |
| EBITDA Ratio | -$4.09 | -$18.19 | -$12.75 | -$10.83 |
| Operating Income | -$5.99M | -$16.21M | -$27.27M | -$32.61M |
| Operating Income Ratio | -$2.34 | -$16.36 | -$12.77 | -$10.85 |
| Other Income/Expenses (Net) | -$6.49M | -$3.80M | -$3.43M | $270000.00 |
| Income Before Tax | -$12.48M | -$20.02M | -$30.70M | -$32.34M |
| Income Before Tax Ratio | -$4.88 | -$20.20 | -$14.38 | -$10.76 |
| Income Tax Expense | $0.00 | $0.00 | -$1276.00 | -$1.00 |
| Net Income | -$12.48M | -$20.02M | -$30.70M | -$32.34M |
| Net Income Ratio | -$4.88 | -$20.20 | -$14.38 | -$10.76 |
| EPS | -$0.23 | -$0.37 | -$0.56 | -$0.59 |
| Diluted EPS | -$0.23 | -$0.37 | -$0.56 | -$0.59 |
| Weighted Avg Shares Outstanding | $54.84M | $54.72M | $54.59M | $54.48M |
| Weighted Avg Shares Outstanding (Diluted) | $54.84M | $54.72M | $54.59M | $54.48M |
Over the past four quarters, Cara Therapeutics, Inc. demonstrated steady revenue growth, increasing from $3.004M in Q4 2023 to $2.56M in Q3 2024. Operating income reached -$5.99M in Q3 2024, maintaining a consistent -234% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$10.44M, reflecting operational efficiency. Net income rose to -$12.48M, with EPS at -$0.23. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan